A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
复制标题
DOI：
10.1016/j.msard.2023.104574
复制
发表时间：
2023-03
影响因子：
4
通讯作者：
Levit, Elle
中科院分区：
文献类型：
--
作者：
Stoll, Sharon;Desai, Shree;Levit, Elle
Patients with multiple sclerosis (MS) are commonly treated with anti-CD20 therapies. Reduced seroconversion following COVID-19 vaccination in patients receiving certain anti-CD20 therapies has been reported; however, the immune response following natural infection is poorly characterised. This study aimed to retrospectively evaluate COVID-19 antibody responses after vaccination and natural infection in patients treated with anti-CD20 therapies. We performed a retrospective review evaluating COVID-19 seroconversion and anti-spike glycoprotein antibody titres in double-vaccinated patients with MS, or related neuroinflammatory conditions, treated with anti-CD20 therapies (N = 30) with a confirmed history of natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (n = 14) or without infection (control; n = 16). This single-centre study was performed at the Yale Multiple Sclerosis Center, where patients treated with anti-CD20 therapies (ocrelizumab, n = 21; rituximab, n = 5; ofatumumab, n = 4) were systematically checked for SARS-CoV-2 anti-spike antibody levels throughout the pandemic. Data were collected from March 2020 to March 2022. All patients had received at least two doses of a Food and Drug Administration (FDA)-approved COVID-19 vaccine. Qualitative anti-spike antibody seropositivity was determined based on test-specific laboratory reference ranges. For a subset of patients (n = 18), quantitative anti-spike antibody levels were assessed via DiaSorin LIAISON® chemiluminescence immunoassay (positive titre was defined as ≥ 13). Vaccination and infection dates were also recorded, and patients were monitored for adverse COVID-19-related health effects. Overall, 15/30 (50.0%) patients seroconverted following double vaccination. After infection, 13/14 (92.9%) seroconverted, while 6/16 (37.5%) uninfected patients seroconverted after vaccination. For the 18 patients with quantitative anti-spike antibody titres, mean titre post-vaccination was 37.4. Mean antibody titres were significantly higher after infection: 540.3 versus 20.1 in the control group (p < 0.05). Of the 14 infected patients, 13 had mild COVID-19 symptoms and one was asymptomatic. No hospitalisations or deaths were reported. This study reports that SARS-CoV-2 anti-spike antibody titres in double-vaccinated MS patients treated with anti-CD20 therapies were significantly increased post-infection compared with the control group. Patients treated with anti-CD20 therapy who had confirmed infections displayed mild or asymptomatic infection. These results provide reassurance that anti-CD20 therapies in double-vaccinated patients do not preclude an appropriate SARS-CoV-2 antibody response post-infection.
登录
查看更多内容
影响因子：
16.6
作者：
Pérez-Alós L;Armenteros JJA;Madsen JR;Hansen CB;Jarlhelt I;Hamm SR;Heftdal LD;Pries-Heje MM;Møller DL;Fogh K;Hasselbalch RB;Rosbjerg A;Brunak S;Sørensen E;Larsen MAH;Ostrowski SR;Frikke-Schmidt R;Bayarri-Olmos R;Hilsted LM;Iversen KK;Bundgaard H;Nielsen SD;Garred P
通讯作者：
Garred P
影响因子：
7.3
作者：
通讯作者：
--
疫苗诱导的人类针对 COVID-19 的保护的免疫机制。
DOI：
10.1038/s41577-021-00578-z
发表时间：
2021-08
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
Sadarangani M;Marchant A;Kollmann TR
通讯作者：
Kollmann TR
影响因子：
11.2
作者：
Tallantyre EC;Vickaryous N;Anderson V;Asardag AN;Baker D;Bestwick J;Bramhall K;Chance R;Evangelou N;George K;Giovannoni G;Godkin A;Grant L;Harding KE;Hibbert A;Ingram G;Jones M;Kang AS;Loveless S;Moat SJ;Robertson NP;Schmierer K;Scurr MJ;Shah SN;Simmons J;Upcott M;Willis M;Jolles S;Dobson R
通讯作者：
Dobson R
影响因子：
3.7
作者：
Cross AH;Delgado S;Habek M;Davydovskaya M;Ward BJ;Cree BAC;Totolyan N;Pingili R;Mancione L;Hu X;Sullivan R;Su W;Zielman R;Gupta AD;Montalban X;Winthrop K
通讯作者：
Winthrop K